Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma.
Aplastic anemia
Immunotherapy
Melanoma
Nivolumab
Programmed death 1 inhibitor
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
29
11
2018
accepted:
29
11
2018
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.
Identifiants
pubmed: 30792642
doi: 10.1159/000495980
pii: cro-0012-0029
pmc: PMC6381922
doi:
Types de publication
Case Reports
Langues
eng
Pagination
29-32Références
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
Case Rep Oncol. 2016 Jun 27;9(2):373-8
pubmed: 27462240
Case Rep Oncol. 2016 Nov 7;9(3):691-697
pubmed: 27920704
Ann Oncol. 2017 Jul 1;28(7):1672-1673
pubmed: 28407116
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
J Oncol Pharm Pract. 2019 Jan;25(1):221-225
pubmed: 28825374
Melanoma Res. 2017 Dec;27(6):635-637
pubmed: 28872489
Exp Hematol Oncol. 2018 Mar 20;7:6
pubmed: 29568696